Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
PLOS ONE | www.plosone.org 1
December 2013 | Volume 8 | Issue 12 | e82027
Child Survival Working Group
Accessed: 26.10.2019
This concept note describes the methods used to assess the prevalence of any HIVDR and HIVDR by PMTCT exposure among children less than 18 months of age using remnant dried blood spot specimens from early infant diagnosis over a 12-month period
Guidance Document
Unite for Children
This six-day training is intended for case managers/community health volunteers/field supervisors who help households affected by HIV in India.
Zhou et al. Int J Ment Health Syst (2019) 13:10 https://doi.org/10.1186/s13033-019-0263-1
Research Article
PLOS ONE | https://doi.org/10.1371/journal.pone.0190785 January 10, 2018
Child Survival Working Group
Accessed: 02.11.2019
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
Helping Children Live with HIV offers a holistic approach by building on the existing knowledge of parents and caregivers and respecting the importance of other local resources. It integrates health care, illness prevention, and psychosocial support for children and families coping with poverty, foo...d insecurity, emotional trauma, loss, as well as stigma and discrimination.
This guide is intended for broad use by parents, family members, and health workers in home settings and throughout community-based health programs.
To learn more, view the table of contents and a sample chapter, and to buy your copy of this essential new resource from Hesperian.
more
Guidance | Preparedness - Response and early recovery - Recovery and reconstruction
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released i...n 2018 on diagnosing, preventing, and managing cryptococcal disease. In response to important new evidence that became available in 2021, these new guidelines strongly recommend a single high dose of liposomal amphotericin B as part of the preferred induction regimen for the treatment of cryptococcal meningitis in people living with HIV. This simplified regimen - a single high dose of liposomal amphotericin B paired with other standard medicines (flucytosine and fluconazole) - is as effective as the previous WHO standard of care, with the benefits of lower toxicity and fewer monitoring demands.
The objective of these guidelines is to provide updated, evidence-informed recommendations for treating adults, adolescents and children living with HIV who have cryptococcal disease. These guidelines are aimed at HIV programme managers, policymakers, national treatment advisory boards, implementing partners and health-care professionals providing care for people living with HIV in resource-limited settings with a high burden of cryptococcal disease.
more
Cryptococcal disease, particularly cryptococcal meningitis is a significant cause of morbidity and mortality among people living with HIV with advanced HIV disease. It is estimated that it is responsible for nearly 19% of AIDS-related mortality, second only to tuberculosis. Rapid screening, diagnosi...s and linking to appropriate treatment are critical actions national programs must take to reduce the burden of disease.
WHO in 2022 introduced updated guidelines for diagnosing, preventing, and managing cryptococcal disease among adults, adolescents and children living with HIV. This policy brief provides a summary of the key recommendations, clinical considerations, and also stresses the importance of ensuring access to life-saving antifungals. There is an urgent need for countries to scale-up management for not just cryptococcal meningitis, but address cryptococcal disease in the context of a package of care for advanced HIV disease as recommended by WHO.
more